Results 121 to 130 of about 47,032 (177)
BiomimeticsRadiation-induced skin injury (RISI) is one of the most common complications of radiotherapy, severely compromising patients’ quality of life. However, no standardized treatment has yet been established.
Yinhui Wang +7 more
doaj +1 more source
EJNMMI PhysicsBackground Zirconium-89 (89Zr) is a highly valued diagnostic radionuclide for positron emission tomography (PET) due to its long physical half-life of 78.4 h and decay characteristics, being preferred for the radiolabelling of nanoparticles and slow ...
Diana Cocioabă +7 more
doaj +1 more source
Chelator impact: investigating the pharmacokinetic behavior of copper-64 labeled PD-L1 radioligands
EJNMMI Radiopharmacy and ChemistryBackground Programmed cell death ligand 1 (PD-L1) plays a critical role in the tumor microenvironment and overexpression in several solid cancers has been reported. This was associated with a downregulation of the local immune response, specifically of T-
Fabian Krutzek +2 more
doaj +1 more source
Terbium-149 production: a focus on yield and quality improvement towards preclinical application
Scientific ReportsTerbium-149 (T1/2 = 4.1 h, Eα = 3.98 MeV (16.7%), 28 µm range in tissue) is a radionuclide with potential for targeted alpha therapy. Due to the negligible emission of α-emitting daughter nuclides, toxicity to healthy tissue may be reduced in comparison ...
C. Favaretto +11 more
doaj +1 more source
PharmaceuticalsBackground/Objectives: The cell surface proteoglycan glypican-3 (GPC3) is reportedly overexpressed in hepatocellular carcinoma (HCC) tissues, but not in benign liver tissues, rendering this protein a potential target for radionuclide theranostic ...
Eva-Maria Burger +9 more
doaj +1 more source
Biodistribution and Imaging of the 99mTc-Glutathione Radiopharmaceutical in White Rats Induced with Cancer [PDF]
, 2013 99mTc-glutathione (99mTc-GSH) is a radiopharmaceuticalwhich is potentially used as a cancer diagnostic kit. As with other radiopharmaceuticals, before applied in humans, including in clinical trials, 99mTc-GSH needs to go through a series of preclinical ...
Iswahyudi, I. (Iswahyudi) +2 more
core
Small ScienceThe selection and optimization of therapies for cancer patients urgently need personalization. Portable point‐of‐care electronic biosensors emerge as a groundbreaking solution contributing to better decision‐making in precision oncology.
Trang‐Anh Nguyen‐Le +8 more
doaj +1 more source